Recurrence in Oral Premalignancy: Clinicopathologic and Immunohistochemical Analysis
Maria Georgaki,
Dimitris Avgoustidis,
Vasileios Ionas Theofilou,
Evangelia Piperi,
Efstathios Pettas,
Demos G. Kalyvas,
Dimitrios Vlachodimitropoulos,
Christos Perisanidis,
Andreas C. Lazaris,
Nikolaos G. Nikitakis
Affiliations
Maria Georgaki
Department of Oral Medicine & Pathology and Hospital Dentistry, School of Dentistry, National and Kapodistrian University of Athens, 11527 Athens, Greece
Dimitris Avgoustidis
Department of Oral and Maxillofacial Surgery, “Evaggelismos” General Hospital, School of Dentistry, National and Kapodistrian University of Athens, 10676 Athens, Greece
Vasileios Ionas Theofilou
Department of Oral Medicine & Pathology and Hospital Dentistry, School of Dentistry, National and Kapodistrian University of Athens, 11527 Athens, Greece
Evangelia Piperi
Department of Oral Medicine & Pathology and Hospital Dentistry, School of Dentistry, National and Kapodistrian University of Athens, 11527 Athens, Greece
Efstathios Pettas
Department of Oral Medicine & Pathology and Hospital Dentistry, School of Dentistry, National and Kapodistrian University of Athens, 11527 Athens, Greece
Demos G. Kalyvas
Department of Oral & Maxillofacial Surgery, School of Dentistry, National and Kapodistrian University of Athens, 11527 Athens, Greece
Dimitrios Vlachodimitropoulos
Department of Forensic Medicine-Toxicology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
Christos Perisanidis
Department of Oral & Maxillofacial Surgery, School of Dentistry, National and Kapodistrian University of Athens, 11527 Athens, Greece
Andreas C. Lazaris
Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece
Nikolaos G. Nikitakis
Department of Oral Medicine & Pathology and Hospital Dentistry, School of Dentistry, National and Kapodistrian University of Athens, 11527 Athens, Greece
Oral leukoplakia (OL) has a propensity for recurrence and malignant transformation (MT). Herein, we evaluate sociodemographic, clinical, microscopic and immunohistochemical parameters as predictive factors for OL recurrence, also comparing primary lesions (PLs) with recurrences. Thirty-three patients with OL, completely removed either by excisional biopsy or by laser ablation following incisional biopsy, were studied. Selected molecules associated with the STAT3 oncogenic pathway, including pSTAT3, Bcl-xL, survivin, cyclin D1 and Ki-67, were further analyzed. A total of 135 OL lesions, including 97 PLs and 38 recurrences, were included. Out of 97 PLs, 31 recurred at least once and none of them underwent MT, during a mean follow-up time of 48.3 months. There was no statistically significant difference among the various parameters in recurrent vs. non-recurrent PLs, although recurrence was most frequent in non-homogeneous lesions (p = 0.087) and dysplastic lesions recurred at a higher percentage compared to hyperplastic lesions (34.5% vs. 15.4%). Lower levels of Bcl-xL and survivin were identified as significant risk factors for OL recurrence. Recurrences, although smaller and more frequently homogeneous and non-dysplastic compared to their corresponding PLs, exhibited increased immunohistochemical expression of oncogenic molecules, especially pSTAT3 and Bcl-xL. Our results suggest that parameters associated with recurrence may differ from those that affect the risk of progression to malignancy and support OL management protocols favoring excision and close monitoring of all lesions.